Canada and CSL Seqirus – a Global Leader in Influenza Vaccines, Agree on New Pandemic Preparedness Contract
Canada’s Public Health Agency has signed a new agreement with CSL Seqirus to provide millions of doses of adjuvanted cell‑based influenza vaccine in the event of a WHO‑declared pandemic. The contract replaces a previous egg‑based arrangement and builds on the six‑year rollout of Flucelvax in Canada’s seasonal flu program. Cell‑based manufacturing offers faster scale‑up, less reliance on eggs, and greater flexibility against emerging strains. Officials highlighted the deal as a critical step to safeguard public health amid rising avian‑influenza threats.
Alnylam Canada ULC – Receives Positive Recommendation From Canada’s Drug Agency (CDA) for the Public Reimbursement of AMVUTTRA® (Vutrisiran Injection),...
Alnylam Canada received a positive recommendation from Canada’s Drug Agency to list AMVUTTRA® (vutrisiran) for public reimbursement in adult patients with cardiomyopathy caused by wild‑type or hereditary ATTR amyloidosis. The therapy, approved by Health Canada in December 2025, expands the...
Aramis Biotechnologies and the Biologics Manufacturing Centre (BMC) Inc. – Announce the Successful Delivery of a Seasonal Influenza Vaccine in...
Aramis Biotechnologies and the Biologics Manufacturing Centre (BMC) announced they have completed formulation, aseptic fill‑finish, and clinical packaging for Aramis’s seasonal influenza vaccine. The milestone delivers clinical‑grade material for Phase 1/2 trials, meeting regulatory quality and safety requirements. The achievement underscores...
Aspect Biosystems and Novo Nordisk – Enter New Phase of Partnership to Develop Curative Medicines for Diabetes
Novo Nordisk and Aspect Biosystems have entered a new partnership phase to develop curative cellular medicines for diabetes. Aspect will acquire Novo Nordisk's stem‑cell‑derived islet and hypoimmune technologies and lead development, manufacturing, and commercialization, while Novo Nordisk retains rights to...
VIDO – Five Ways Our Research Strengthened Animal Health in 2025
In 2025 the University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) tackled five critical animal‑health challenges, from a first‑record H5N1 outbreak in dairy cattle to a world‑first chlamydia vaccine for endangered koalas. Researchers demonstrated natural immunity in infected cows,...